SCIENTIFIC EVIDENCE

PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.

International journal of immunopathology and pharmacology

Sun S, Du G, Xue J, Ma J, Ge M, Wang H, Tian J.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2018

Cancer Research

Immunology

No items found.

Key Finding

These findings indicate that PCC0208009 can potentiate the anti-tumor efficacy of temozolomide and suggest that combination of IDO inhibitor-based immunotherapy with chemotherapy is a potential strategy for brain tumor treatment.

Countstar Connection

Within the study, a Countstar instrument measured cell number and viability in the study's cell samples during the study's growth assessment.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online